Currently, pre-treatment is no longer administered at most centers, and the duration of DAPT has been shortened to 3 months or even 1 month. Moreover, at certain centers, aspirin alone is prescribed after TAVR (1) (2) (3) , with a similar rate of thromboembolic events and a strong trend toward a decrease in bleeding risks.
This hypothesis is currently being explored in the ARTE (Aspirin Versus Aspirin þ Clopidogrel Following Transcatheter Aortic Valve Implantation) study (4), a randomized study of 300 patients not on oral anticoagulation (OAC) who will be treated after TAVR with DAPT with aspirin for at least 6 months and clopidogrel for 3 months or single-antiplatelet therapy with aspirin alone for at least 6 months. The primary endpoint will be a composite of death, myocardial infarction (MI), ischemic stroke or transient ischemic attack, and lifethreatening or major bleeding at 3 months. This is an even more complex problem in the 25% to The first important lesson to be drawn from this study is that prescribing antiplatelet therapy for patients with AF who are already on long-term anticoagulation does not confer any benefits. Indeed, the investigators show that after a median follow-up period of 13 months, the risk for stroke, major cardiac events, or death was similar, regardless of the treatment implemented. Conversely, the risk for major or life-threatening bleeding was almost twice as high (hazard ratio: 1.85; 95% confidence interval: 
